research P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
Search
for
Sort by
Research
390-420 / 1000+ results 
research Understanding Eyebrow and Eyelash Involvement in Patients with Alopecia Areata and Responsiveness to Treatment with Baricitinib.
Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.
research Synthesis and Biological Evaluation of 4-(4-(Alkyl-and Phenylaminocarbonyl)benzoyl)benzoic Acid Derivatives as Non-steroidal Inhibitors of Steroid 5α-Reductase Isozymes 1 and 2
The compound 4c effectively inhibits the enzyme linked to hair loss.
research 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2
Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
research Steroid 5α-reductase inhibition by polymethoxyflavones
Certain natural compounds can block an enzyme linked to prostate enlargement and hair loss, showing potential for new treatments.
research Synthesis, antiproliferative, acute toxicity and assessment of antiandrogenic activities of some newly synthesized steroidal lactams
research Baricitinib as the first systemic treatment for severe alopecia areata
Baricitinib is effective as a treatment for severe hair loss.
research Combination of baricitinib and conventional immunomodulating therapy for alopecia totalis
Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
research Cinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase
Cinnamomi cortex may help treat prostate enlargement by reducing related proteins.
research Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
research Advances in the understanding of androgen receptor structure and function and in the development of next-generation AR-targeted therapeutics
research Synthesis and biological evaluation of 3-tetrazolo steroidal analogs: Novel class of 5α-reductase inhibitors
3-tetrazolo steroidal analogs can strongly inhibit the enzyme linked to hair loss.
research 5α-Reductase inhibitors in androgenetic alopecia
research Androgenetic alopecia: a new therapeutical approach
research Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results
Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research Etrasimod for alopecia areata: The scenario for a less extensive and moderate form
Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
research Drug development to improve androgenetic alopecia on the Traditional Chinese Medicine theory
PMC shows promise as a treatment for hair loss.
research Treatment of Alopecia Areata with Simvastatin/Ezetimibe
Simvastatin/ezetimibe may help treat new cases of alopecia areata but not long-term cases.
research STUDY THE EFFECT OF FINASTERIDE MICROEMULSION GEL ON THE TREATMENT OF MEN WITH MILD TO MODERATE ACNE
research Upadacitinib for the management of severe alopecia areata in adolescent patients: a single-centre retrospective study
Upadacitinib is effective and safe for treating severe alopecia areata in teens.
research Subjects with mild alopecia benefit from aminexil clinical 5: results of a large international observational study
Aminexil clinical 5 effectively reduces hair loss and is well-tolerated.
research Baricitinib for alopecia areata
Baricitinib is effective in promoting hair growth in severe alopecia areata.
research 3,3-Diphenylpentane skeleton as a steroid skeleton substitute: Novel inhibitors of human 5α-reductase 1
A new compound effectively inhibits human 5α-reductase 1.
research LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.
LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
research BH08 Unprovoked pulmonary emboli in a patient with alopecia areata treated with ritlecitinib: a case report
Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
research UHPLC-Q-Orbitrap HRMS-based Metabolomics and In Silico Studies on 5-α-Reductase, JAK1, JAK2, and JAK3 of <i>Albizia saponaria</i> L.: Application to Alopecia
Albizia saponaria bark extract may help treat hair loss.
research Sudden improvement of alopecia universalis and psoriatic arthritis while receiving upadacitinib: a case-based review
Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
research Squaric Acid Dibutylester Promotes Innate Immune-Driven Hair Growth with CD206+ Macrophage Accumulation in the Dermis
Squaric acid dibutylester promotes hair growth by activating immune cells, especially macrophages.
research Upadacitinib for the treatment of alopecia areata – A case report
Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.